Vanguard Capital Management
AVXL icon

Vanguard Capital Management’s Anavex Life Sciences AVXL Stock Holding History

Vanguard Capital Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5M Buy
4,054,589
+190,639
+5% +$564K ﹤0.01% 2784
2026
Q1 		$11.9M Buy
+3,863,950
New +$16.7M ﹤0.01% 2634

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Capital Management's AVXL Position: Q2 2026 in Review

Vanguard Capital Management increased its Anavex Life Sciences (AVXL) stake by 4.9% in Q2 2026, buying an estimated $564K and bringing the position to 4,054,589 shares worth $10.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2784.

Vanguard Capital Management first reported a position in AVXL in Q1 2026 and has held it in 2 quarters since. The position peaked at $11.9M in Q1 2026. 177 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Vanguard Capital Management held 4,054,589 shares of Anavex Life Sciences worth $10.5M as of Q2 2026.
  • Vanguard Capital Management bought 190,639 Anavex Life Sciences shares in Q2 2026, an estimated $564K.
  • Anavex Life Sciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2784 holding.
  • Vanguard Capital Management first reported a position in Anavex Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Anavex Life Sciences position peaked at $11.9M in Q1 2026.
  • 177 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.